Show simple item record

dc.contributor.authorSchneyer, Alan
dc.contributor.authorAndrzejewski, Danielle
dc.contributor.authorBurnside, Amy
dc.contributor.authorBrown, Melissa
dc.date2022-08-11T08:08:14.000
dc.date.accessioned2022-08-23T15:47:11Z
dc.date.available2022-08-23T15:47:11Z
dc.date.issued2014-05-20
dc.date.submitted2014-10-10
dc.identifier.doi10.13028/awkd-ky55
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27923
dc.description<p>Abstract of poster presented at the 2014 UMass Center for Clinical and Translational Science Research Retreat, held on May 20, 2014 at the University of Massachusetts Medical School, Worcester, Mass.</p>
dc.description.abstractBoth type 1 and type 2 diabetes involve loss of functional pancreatic B-cells which is driving research into potential replacement sources. Expansion of functional B-cell mass, such as through induction of B-cell neogenesis or through transdifferentiation of A-cells into functional B-cells represent appealing therapeutic solutions to restoring glucose control. To date, however, these processes have been induced through genetic manipulation or severe pancreatic injury. It remains to be determined whether transdifferentiation or neogenesis contribute to functional B-cell mass under normal physiological conditions and/or contribute to B-cell expansion and how these processes are regulated. We have reported that inactivation of the activin antagonist follistatin like-3 (FSTL3) resulted in a 2-fold increase in mean islet size with an enlarged B-cell component. We hypothesized that the B-cell expansion resulted from accelerated A- to B-cell transdifferentiation that was induced by the enhanced activin bioavailability of the FSTL3 KO mouse. We first demonstrated that activin suppressed important A-cell gene expression and promoted B-cell gene expression in A- and B-cell lines. We then used cell sorting based on natural fluorescence of A- and B-cells to achieve >95% enrichment of these cell populations. Activin treatment of these primary cells also suppressed A-cell gene expression including ARX. To explore whether activin had this effect in vivo, we used lineage tracing to label A-cells with YFP using Gluc-Cre/YFP mice crossed with FSTL3 KO mice. Cell sorting identified 2 additional populations, YFP labeled A-cells and YFP labeled B-cells with the number of YFP+Ins+ cells increased in FSTL3 KO islets compared to WT. These results suggest that A- to B-cell transdifferentiation occurs in the absence of genetic drivers or injury, that this process is increased in FSTL3 KO mice, and that activin may promote transdifferentiation to increase B-cell mass. Supported by JDRF (17-2012-414)
dc.formatyoutube
dc.language.isoen_US
dc.rightsCopyright the Author(s)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/
dc.subjectCell Biology
dc.subjectCellular and Molecular Physiology
dc.subjectDevelopmental Biology
dc.subjectNutritional and Metabolic Diseases
dc.subjectTranslational Medical Research
dc.titleTransdifferentiation of α- to β-cells is Enhanced in FSTL3 KO Mice
dc.typePoster Abstract
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1351&amp;context=cts_retreat&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/cts_retreat/2014/posters/131
dc.identifier.contextkey6226576
refterms.dateFOA2022-08-23T15:47:11Z
html.description.abstract<p>Both type 1 and type 2 diabetes involve loss of functional pancreatic B-cells which is driving research into potential replacement sources. Expansion of functional B-cell mass, such as through induction of B-cell neogenesis or through transdifferentiation of A-cells into functional B-cells represent appealing therapeutic solutions to restoring glucose control. To date, however, these processes have been induced through genetic manipulation or severe pancreatic injury. It remains to be determined whether transdifferentiation or neogenesis contribute to functional B-cell mass under normal physiological conditions and/or contribute to B-cell expansion and how these processes are regulated.</p> <p>We have reported that inactivation of the activin antagonist follistatin like-3 (FSTL3) resulted in a 2-fold increase in mean islet size with an enlarged B-cell component. We hypothesized that the B-cell expansion resulted from accelerated A- to B-cell transdifferentiation that was induced by the enhanced activin bioavailability of the FSTL3 KO mouse. We first demonstrated that activin suppressed important A-cell gene expression and promoted B-cell gene expression in A- and B-cell lines. We then used cell sorting based on natural fluorescence of A- and B-cells to achieve >95% enrichment of these cell populations. Activin treatment of these primary cells also suppressed A-cell gene expression including ARX. To explore whether activin had this effect in vivo, we used lineage tracing to label A-cells with YFP using Gluc-Cre/YFP mice crossed with FSTL3 KO mice. Cell sorting identified 2 additional populations, YFP labeled A-cells and YFP labeled B-cells with the number of YFP+Ins+ cells increased in FSTL3 KO islets compared to WT. These results suggest that A- to B-cell transdifferentiation occurs in the absence of genetic drivers or injury, that this process is increased in FSTL3 KO mice, and that activin may promote transdifferentiation to increase B-cell mass. Supported by JDRF (17-2012-414)</p>
dc.identifier.submissionpathcts_retreat/2014/posters/131


Files in this item

Thumbnail
Name:
Schneyer.pdf
Size:
24.46Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright the Author(s)
Except where otherwise noted, this item's license is described as Copyright the Author(s)